TRIPTAN/DIHYDROERGOTAMINE AGENTS PRIOR AUTHORIZATION REQUEST

PRESCRIBER FAX FORM

ONLY the prescriber may complete and fax this form. This form is for prospective, concurrent, and retrospective reviews.

Incomplete forms will be returned for additional information. The following documentation is required for prior authorization consideration. For formulary information and to download additional forms, please visit https://www.bcbstx.com/provider/medicaid/rx_prior_auth.html

PATIENT AND INSURANCE INFORMATION					Today's Date:		
Patient Name (First):	Last:				M:	DOB (mm/dd/yy):	
Patient Address:	City, State, Zip:					Patient Telephone:	
BCBSTX ID Number:		L		Group Number:			
PRESCRIBER/CLINIC INFORM	ATION						
Prescriber Name:				Specialty:		Contact Name:	
Clinic Name:		Clinic Address:					
City, State, Zip:			Phone	Phone #:		Secure Fax #:	
PLEASE ATTACH ANY ADDITI	ONAL INFOR	MATION THAT	SHOUI	LD BE CONSIDERED	WITH	THIS REQUEST	
Patient's Diagnosis-ICD code p							
Medication Requested: *Your request will be reviewe	d for the gen	eric equivalent ı	unless	Strength you specify brand i		uired.	
Dosing Schedule: Quantity per Month:							
						Yes No	
	ig prophylaction agents:	migraine medica	ation? .			Yes No	
ii iio, piease provide ii	-ason						
4. Will the patient be using th (i.e., triptan, 5HT-1F, ergot	e requested a amine, acute	gent in combinati CGRP)?	ion with	n another acute migra	ine 5H	Yes No	
	-	-			of thi	s diagnosis (Please specify if	
brand name, generic, exter						Data (a):	
		ate(s):					
		ate(s):					
	electing the re	equested medic	ation c	over alternatives (e.g.,		aindications, allergies or history of	
7. Please list all other agents	the patient wi	II be taking for the	e treatr	ment of the diagnosis	provid	led:	
Drogovihov ov Authorized Sign	2011101						
Prescriber or Authorized Sign Prior Authorization of Benefits is no treating physician can determine w regarding benefits, conditions, limit complete and the requested service Note: Payment is subject to member	at the practice of that medications ations, and excl as are medically	are appropriate for lusions. The submit indicated and nec	r a patie tting pro essary t	ent. Please refer to the a vider certifies that the in to the health of the patie	edical ju pplicab oformati	te: adgment of a treating physician. Only a ale plan for the detailed information and provided is true, accurate, and	
Please fax or mail this form to: Prime Therapeutics LLC, Clinical Review Department 2900 Ames Crossing Road Eagan, Minnesota 55121			1	CONFIDENTIALITY NOTICE: This communication is intended only for the use of the individual entity to which it is addressed and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in			
TOLL FREE				error, please notify the sender immediately by telephone at			
Fax: 877.243.6930 Phone: 855.457.0407				866.202.3474 and return the original message to Prime			

Therapeutics via U.S. Mail. Thank you for your cooperation.